Francisco J Ortega1,2, Zaida Agüera1,3, Mònica Sabater1,2, José M Moreno-Navarrete1,2, Isabel Alonso-Ledesma1,2, Gemma Xifra2, Patricia Botas4, Elías Delgado4, Susana Jimenez-Murcia1,3, José C Fernández-García1,5, Francisco J Tinahones1,5, Rosa M Baños1,6, Cristina Botella1,7, Rafael de la Torre1,8,9, Gema Frühbeck1,10, Amaia Rodrigüez1,10, Xavier Estivill11, Felipe Casanueva1,12, Wifredo Ricart1,2, Fernando Fernández-Aranda1,3, José M Fernández-Real1,2. 1. CIBER de la Fisiopatología de la Obesidad y la Nutrición (CIBEROBN), and Instituto de Salud Carlos III (ISCIII), Madrid, Spain. 2. Service of Diabetes, Endocrinology and Nutrition (UDEN), and Institut d'Investigació Biomédica de Girona (IdIBGi), Girona, Spain. 3. Department of Psychiatry, University Hospital of Bellvitge (IDIBELL), and Department of Clinical Sciences, School of Medicine, University of Barcelona, Barcelona, Spain. 4. Hospital Central de Asturias, Oviedo, Spain. 5. Department of Diabetes, Endocrinology and Nutrition, Hospital Clínico Universitario Virgen de Victoria, Málaga, Spain. 6. Department of Psychological, Personality, Evaluation and Treatment, University of Valencia, Valencia, Spain. 7. Department of Basic Psychology, Clinic and Psychobiology, University Jaume I, Castelló, Spain. 8. Department of Pharmacology, School of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain. 9. Human Pharmacology and Clinical Neurosciences Research Group, Neuroscience Research Program, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. 10. Department of Endocrinology and Nutrition, Clínica Universidad de Navarra, University of Navarra, Pamplona, Spain. 11. Center for Genomic Regulation (CRG) and CIBER de Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain. 12. Endocrine Division, Complejo Hospitalario U. de Santiago, Santiago de Compostela University, Santiago de Compostela, Spain.
Abstract
SCOPE: Changes in genetic variations affecting the taste receptor, type 2, member 38 (TAS2R38) may identify the interacting mechanism leading to obesity and potential associations with proteins partaking in innate immunity, such as surfactant protein D (SPD) and mannan-binding lectin (MBL). METHODS AND RESULTS: We evaluated haplotypes of the bitter-taste receptor TAS2R38 in an identification sample of 210 women in different weight conditions, including anorexia nervosa and obesity. The association with SPD and MBL was tested in an independent sample picturing general population (n = 534). The relationship with obesity was validated in an extended final sample of 1319 participants. In the sample comprised of women in extreme weight conditions, increased obesity was identified in AVI/AVI subjects (OR = 2.5 [1.06-6.11], p = 0.035). In the sample picturing general population, increased SPD and MBL concentrations were found in nonsmoking AVI carriers. In this cohort, smoking and obesity blunted associations between TAS2R38 haplotypes and SPD and MBL. In the extended sample, the association of AVI/AVI haplotypes with increased obesity was also identified (OR = 1.4 [0.99/1.85], p = 0.049), being more robust in subjects aged <40 years (OR = 1.9 [1.06/3.42], p = 0.031). CONCLUSION: Current data reinforce the impact of TAS2R38 gene on phenotypic and clinical outputs affecting obesity, showing significant associations with extreme weight conditions (i.e., obesity and anorexia nervosa), and changes in both olfactory capacity and immune traits.
SCOPE: Changes in genetic variations affecting the taste receptor, type 2, member 38 (TAS2R38) may identify the interacting mechanism leading to obesity and potential associations with proteins partaking in innate immunity, such as surfactant protein D (SPD) and mannan-binding lectin (MBL). METHODS AND RESULTS: We evaluated haplotypes of the bitter-taste receptor TAS2R38 in an identification sample of 210 women in different weight conditions, including anorexia nervosa and obesity. The association with SPD and MBL was tested in an independent sample picturing general population (n = 534). The relationship with obesity was validated in an extended final sample of 1319 participants. In the sample comprised of women in extreme weight conditions, increased obesity was identified in AVI/AVI subjects (OR = 2.5 [1.06-6.11], p = 0.035). In the sample picturing general population, increased SPD and MBL concentrations were found in nonsmoking AVI carriers. In this cohort, smoking and obesity blunted associations between TAS2R38 haplotypes and SPD and MBL. In the extended sample, the association of AVI/AVI haplotypes with increased obesity was also identified (OR = 1.4 [0.99/1.85], p = 0.049), being more robust in subjects aged <40 years (OR = 1.9 [1.06/3.42], p = 0.031). CONCLUSION: Current data reinforce the impact of TAS2R38 gene on phenotypic and clinical outputs affecting obesity, showing significant associations with extreme weight conditions (i.e., obesity and anorexia nervosa), and changes in both olfactory capacity and immune traits.
Authors: Alexandria Turner; Martin Veysey; Simon Keely; Christopher J Scarlett; Mark Lucock; Emma L Beckett Journal: Nutrients Date: 2021-02-09 Impact factor: 5.717
Authors: Marta Trius-Soler; Paz A Bersano-Reyes; Clara Góngora; Rosa M Lamuela-Raventós; Gema Nieto; Juan J Moreno Journal: Genes Nutr Date: 2022-07-27 Impact factor: 4.423
Authors: Alexandria Turner; Martin Veysey; Simon Keely; Christopher Scarlett; Mark Lucock; Emma L Beckett Journal: Nutrients Date: 2018-09-20 Impact factor: 5.717